Morris Charles Q 4

What Happened

• Morris Charles Q, Chief Medical Officer of Prelude Therapeutics (PRLD), was granted a derivative award covering 450,000 shares with an acquisition price of $4.70 per share, representing a notional value of $2,115,000. This filing reports an award/grant (derivative), not a cash purchase or open-market trade.

Key Details

• Transaction date: May 1, 2026; Filing date: May 4, 2026 (filed within the normal reporting window).
• Grant size and terms reported: 450,000 shares @ $4.70 per share; total notional value $2,115,000.
• Shares owned after transaction: Not specified in this filing.
• Footnote: The award vests 25% on May 1, 2027, then vests monthly at 1/48 of the total shares thereafter until fully vested, contingent on continued service.
• No immediate sale, cashless exercise, 10b5-1 plan, or tax-withholding transaction is reported in this Form 4.

Context

• This is a typical equity compensation grant to an executive (a bullish signal only in that it aligns incentives; it does not represent an open-market purchase). Because the award is a derivative with a multi-year vesting schedule, the shares are not immediately available to Morris and will vest over time if he remains with the company.